Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study

Table 5 Toxicities during neoadjuvant treatment in the two groups

	non-CC group (n = 129), n (%)				CC group (n = 136), n (%)
	Grade 1	Grade 2	Grade 3	Grade 4-5	Grade 1	Grade 2	Grade 3	Grade 4-5
Total	59 (45.7)	64 (49.6)	5 (3.9)	0	66 (48.5)	63 (46.3)	4 (2.9)	0
Leukopenia	47 (36.4)	29 (22.5)	2 (1.6)	0	51 (37.5)	27 (19.9)	0	0
Neutropenia	22 (17.1)	9 (7.0)	0	0	22 (16.2)	9 (6.6)	0	0
Anemia	5 (3.9)	6 (4.7)	2 (1.6)	0	14 (10.3)	5 (3.7)	0	0
Thrombocytopenia	9 (7.0)	0	1 (0.8)	0	5 (3.7)	0	0	0
Aminotransferase increased	0 (0.0)	1 (0.8)	0	0	6 (4.4)	0	0	0
Bilirubin increased	19 (14.7)	2 (3.1)	0	0	18 (13.2)	2 (1.5)	1 (0.7)	0
Nausea	39 (30.2)	0	0	0	30 (22.1)	1 (0.7)	0	0
Fatigue	58 (45.0)	3 (2.3)	0	0	66 (44.9)	2 (1.5)	0	0
Proctitis/diarrhea	66 (51.2)	36 (27.9)	1 (0.8)	0	66 (48.5)	39 (28.7)	2 (1.5)	0
Cystitis	38 (29.5)	0	0	0	42 (30.9)	0	0	0
Radiodermatitis	75 (58.1)	6 (4.7)	0	0	70 (51.5)	3 (2.2)	0	0

CC: Consolidation chemotherapy.